The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy

PAM4, a new monoclonal antibody (MAb) known as clivatuzumab, is highly reactive with pancreatic cancer and precursor lesions. It is absent from the normal tissues and has limited reactivity with nonpancreatic cancer. The detailed characteristic of the PAM4 epitope is unknown but recent studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Suxia, Jin, Guihua, Wang, Lijuan, Li, Meng, He, Chenchen, Guo, Xijing, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003775/
https://www.ncbi.nlm.nih.gov/pubmed/24818166
http://dx.doi.org/10.1155/2014/268479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003775/
https://www.ncbi.nlm.nih.gov/pubmed/24818166
http://dx.doi.org/10.1155/2014/268479

Ejemplares similares